EC Number   |
Inhibitors |
Structure |
|---|
    1.14.14.154 | (2R,4S)-ketoconazole |
- |
   |
| 1.14.14.154 | (R)-2-(2,4-difluorophenyl)-1,1-difluoro-3-(1H-tetrazol-1-yl)-1-(5-(4-(2,2,2-trifluoroethoxy)phenyl)pyridin-2-yl)propan-2-ol |
i.e. oteseconazole, i.e. VT-1161. 98% inhibition, molar ratio of enzyme/inhibitor/lanosterol was 1:2:50 |
|
| 1.14.14.154 | (R)-3-(1H-1,2,4-triazol-1-yl)butyl 2-chlorobenzoate |
exhibits stronger binding activities than triadimefon but lower binding activities than diniconazole |
|
| 1.14.14.154 | (R)-3-(1H-1,2,4-triazol-1-yl)butyl 3-chlorobenzoate |
affinity with purified CYP51 is very low, exhibits lower binding activities than triadimefon and diniconazole |
|
| 1.14.14.154 | (R)-3-(1H-1,2,4-triazol-1-yl)butyl 4-chlorobenzoate |
exhibits stronger binding activities than triadimefon but lower binding activities than diniconazole |
|
| 1.14.14.154 | (R)-3-(1H-1,2,4-triazol-1-yl)butyl 4-methylbenzoate |
affinity with purified CYP51 is very tight, shows the best binding activities, exhibits stronger binding activities than triadimefon but lower binding activities than diniconazole; no binding affinity with purified CYP51 |
|
| 1.14.14.154 | (R)-3-(1H-1,2,4-triazol-1-yl)butyl benzoate |
exhibits lower binding activities than triadimefon and diniconazole |
|
| 1.14.14.154 | (R)-4'-chloro-N-(1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)ethyl)biphenyl-4-carboxamide |
VNF, complexes CYP51, binding structure, overview |
|
| 1.14.14.154 | (R)-N-(1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)ethyl)-4-(5-phenyl-1,3,4-oxadiazol-2-yl)-benzamide |
- |
|
| 1.14.14.154 | (R)-N-(2-(1H-imidazol-1-yl)-1-phenylethyl)-4'-chlorobiphenyl-4-carboxamide |
- |
|
